PAXgene® Blood miRNA Kit Now Available to Co-purify RNA and miRNA
New kit allows researchers to minimize preanalytical variables for RNA and miRNA
Venlo, The Netherlands - May 18, 2009 - As the importance of miRNA research has risen, so have the demands for a standardized method for co-purification of RNA and miRNA from human blood samples. To address this need, PreAnalytiX, GmbH, a QIAGEN/BD company, has launched the PAXgene Blood miRNA Kit.
Currently, many researchers rely on the PAXgene Blood RNA System, consisting of PAXgene Blood RNA Tubes and PAXgene Blood RNA Kits, for collection and stabilization of human whole blood. The System inhibits RNA degradation and gene induction in vitro resulting in preservation of the gene expression profile that is essential for accurate analysis. However, researchers cannot easily extract and purify the miRNA from these same samples.
"Up to this point, academic, pharma and biobank researchers have been relying primarily on miRNA extraction methods from their blood samples which do not include a stabilization step," said Marie McCluskey, Global Product Manager for Pre-analytical Systems at QIAGEN. "In addition, these methods often lack standardized collection of the sample, and as a result lead to a lack consistency in results."
PAXgene Blood RNA Tubes used in combination with the new PAXgene Blood miRNA Kit comprise the first system available for collecting and stabilizing whole human blood, and co-purifying total RNA enriched for miRNA. PAXgene Blood miRNA protocols are available for both manual as well as automated solutions. For increased efficiency in the lab, this Research Use Only (RUO) protocol can be automated on QIAGEN's QIAcube®. Up to 12 samples can be processed in a single run using the QIAcube variant of the PAXgene Blood miRNA protocol. Additionally, the PAXgene Tissue System (launched in January 2009) is available for studies requiring histological and molecular analyses. The PAXgene Tissue System combines tissue fixation and stabilization with purification of nucleic acids including intact miRNA.
"miRNA is gaining importance in the field of oncology," adds McCluskey. "We have recognized the unmet need of our customers, especially those in Pharma and Biomedical research, to extract and purify miRNA from human whole blood. With the PAXgene Blood miRNA Kit, researchers are able to minimize preanalytical variables for both RNA and miRNA."
More information about these products, including photos, is available at www.qiagen.com.
The PAXgene Blood miRNA Kit is for research use only. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of a disease.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.